Clinical Effects of Platelet-Rich Plasma and Hyaluronic Acid as an Additional Therapy for Talar Osteochondral Lesions Treated with Microfracture Surgery
Restricted accessResearch articleFirst published online August, 2015
Clinical Effects of Platelet-Rich Plasma and Hyaluronic Acid as an Additional Therapy for Talar Osteochondral Lesions Treated with Microfracture Surgery
Osteochondral ankle injuries commonly affect the dome of the talus, and these injuries are a common cause of athletic disability. Various treatment options are available for these injuries including intra-articular hyaluronic acid (HA) and platelet-rich plasma (PRP) injections. The purpose of this study was to compare the effects of HA and PRP as adjunct therapies after arthroscopic microfracture in osteochondral lesions (OCLs) of the talus.
Methods:
In this prospective, randomized blinded study, 40 patients with talar OCLs in their ankle joints were treated with arthroscopic debridement and a microfracture technique. Thirteen randomly selected patients received PRP, 14 patients received HA, and the remaining 13 patients received saline as a control group. The participants were assessed using the American Orthopaedic Foot & Ankle Society (AOFAS) and visual analog pain scale (VAS) scores after a 15.3-month (range, 11-25 months) follow-up.
Results:
Postoperatively, all the groups exhibited significantly increased AOFAS scores and decreased VAS scores compared with their preoperative results (P < .005). The AOFAS scores were significantly increased in the PRP group versus the HA and control groups (P < .005), although the increased AOFAS scores in the HA group versus the control group were also significant (P < .005). Similar to the AOFAS scores, the decrease in the VAS scores was significantly lower in the PRP group versus the HA and control groups (P < .005). In addition, the HA group had significantly lower VAS scores than the control group (P < .005).
Conclusion:
Both PRP and HA injections improved the clinical outcomes of patients who underwent operation for talar OCLs in the midterm period and can be used as adjunct therapies for these patients. Because a single dose of PRP provided better results, we recommend PRP as the primary adjunct treatment option in the talar OCL postoperative period.
AhmadJRaikinSM. Current concepts review: talar fractures. Foot Ankle Int. 2006;27(6):475-482.
2.
AlexanderAHLichtmanDM. Surgical treatment of transchondral talar-dome fractures (osteochondritis dissecans). Long-term follow-up. J Bone Joint Surg Am. 1980;62(4):646-652.
3.
BalazsEADenlingerJL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3-9.
4.
BaumhauerJFAlosaDMRenströmAFTrevinoSBeynnonB. A prospective study of ankle injury risk factors. Am J Sports Med. 1995;23(5):564-570. doi:10.1177/036354659502300508.
5.
BellamyNCampbellJRobinsonV. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005321.
6.
BendinelliPMatteucciEDogliottiG. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol. 2010;225(3):757-766. doi:10.1002/jcp.22274.
7.
BrandlAAngelePRollC. Influence of the growth factors PDGF-BB, TGF-beta1 and bFGF on the replicative aging of human articular chondrocytes during in vitro expansion. J Orthop Res. 2010;28(3):354-360. doi:10.1002/jor.21007.
8.
BrunsJBehrensP. Etiological and pathophysiologic aspects of osteochondrosis dissecans. Arthroskopie. 1998;11(4):166-176.
9.
BuckwalterJABrownTD. Joint injury, repair, and remodeling: roles in post-traumatic osteoarthritis. Clin Orthop Relat Res. 2004;423:7-16.
10.
CanaleSTBeldingRH. Osteochondral lesions of the talus. J Bone Joint Surg Am. 1980;62(1):97-102.
11.
CutticaDJShockleyJAHyerCFBerletGC. Correlation of MRI edema and clinical outcomes following microfracture of osteochondral lesions of the talus. Foot Ankle Spec. 2011;4(5):274-279. doi:10.1177/1938640011411082.
12.
de BoerAGvan LanschotJJStalmeierPF. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?Qual Life Res. 2004;13(2):311-320. doi:10.1023/B:QURE.0000018499.64574.1f.
13.
DeGrootHUzunishviliSWeirRAl-omariAGomesB. Intra-articular injection of hyaluronic acid is not superior to saline solution injection for ankle arthritis: a randomized, double-blind, placebo-controlled study. J Bone Joint Surg Am. 2012;94(1):2-8. doi:10.2106/JBJS.J.01763.
14.
DoralMNBilgeOBatmazG. Treatment of osteochondral lesions of the talus with microfracture technique and postoperative hyaluronan injection. Knee Surg Sports Traumatol Arthrosc. 2012;20(7):1398-1403. doi:10.1007/s00167-011-1856-7.
15.
DraperSDFallatLM. Autogenous bone grafting for the treatment of talar dome lesions. J Foot Ankle Surg. 2000;39:15-23.
16.
EasleyME. Osteochondral lesions of the talus: diagnosis and treatment. Curr Opin Orthop. 2003;14(2):69-73. doi:10.1097/00001433-200304000-00001.
17.
FerkelRDZanottiRMKomendaGA. Arthroscopic treatment of chronic osteochondral lesions of the talus: long-term results. Am J Sports Med. 2008;36(9):1750-1762. doi:10.1177/0363546508316773.
18.
FilardoGKonEDi MartinoA. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229.
19.
FortierLAHackettCHColeBJ. The effects of platelet-rich plasma on cartilage: basic science and clinical application. Op Tech Sports Med. 2011;19:154-159.
20.
GhoshP. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol. 1994;12(1):75-82.
21.
GobbiAFranciscoRALubowitzJHAllegraFCanataG. Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation. Arthroscopy. 2006;22(10):1085-1092. doi:10.1016/j.arthro.2006.05.016.
22.
GoldbergVMBuckwalterJA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthr Cartil. 2005;13(3):216-224. doi:10.1016/j.joca.2004.11.010.
23.
GuneyAAkarMKaramanIOnerMGuneyB. Clinical outcomes of platelet rich plasma (PRP) as an adjunct to microfracture surgery in osteochondral lesions of the talus [published online November30, 2013]. Knee Surg Sports Traumatol Arthrosc. doi:10.1007/s00167-013-2784-5.
24.
HeppleSWinsonIGGlewD. Osteochondral lesions of the talus: a revised classification. Foot Ankle Int. 1999;20(12):789-793. doi:10.1177/107110079902001206.
25.
HuntSAShermanO. Arthroscopic treatment of osteochondral lesions of the talus with correlation of outcome scoring systems. Arthroscopy. 2003;19(4):360-367. doi:10.1053/jars.2003.50047.
26.
JacksonDWLalorPAAbermanHMSimonTM. Spontaneous repair of full-thickness defects of articular cartilage in a goat model. A preliminary study. J Bone Joint Surg Am. 2001;83-A(1):53-64.
27.
KitaokaHBAlexanderIJAdelaarRS. Clinical rating systems for the ankle-hindfoot, midfoot, hallux, and lesser toes. Foot Ankle Int. 1994;15(7):349-353. doi:10.1177/107110079401500701.
28.
KreuzPCSteinwachsMErggeletC. Mosaicplasty with autogenous talar autograft for osteochondral lesions of the talus after failed primary arthroscopic management: a prospective study with a 4-year follow-up. Am J Sports Med. 2006;34(1):55-63. doi:10.1177/0363546505278299.
29.
LeeKBBaiLBChungJYSeonJK. Arthroscopic microfracture for osteochondral lesions of the talus. Knee Surg Sports Traumatol Arthrosc. 2010;18(2):247-253. doi:10.1007/s00167-009-0914-x.
30.
Lopez-VidrieroEGouldingKASimonDASanchezMJohnsonDH. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy. 2010;26(2):269-278. doi:10.1016/j.arthro.2009.11.015.
31.
MankinHJ. The response of articular cartilage to mechanical injury. J Bone Joint Surg Am. 1982;64(3):460-466.
32.
Mei-DanOCarmontMRLaverL. Platelet-rich plasma or hyaluronate in the management of osteochondral lesions of the talus. Am J Sports Med. 2012;40(3):534-541. doi:10.1177/0363546511431238.
33.
MongkhonJMThachMShiQ. Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflamm Res. 2014;63(8):691-701. doi:10.1007/s00011-014-0742-4.
34.
ParkKHNaK. Effect of growth factors on chondrogenic differentiation of rabbit mesenchymal cells embedded in injectable hydrogels. J Biosci Bioeng. 2008;106(1):74-79. doi:10.1263/jbb.106.74.
35.
PujolJPChadjichristosCLegendreF. Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res. 2008;49(3):293-297. doi:10.1080/03008200802148355.
36.
RaikinSM. Stage VI: massive osteochondral defects of the talus. Foot Ankle Clin. 2004;9(4):737-744. doi:10.1016/j.fcl.2004.06.003.
37.
RaikinSMEliasIZogaA. Osteochondral lesions of the talus: localization and morphologic data from 424 patients using a novel anatomical grid scheme. Foot Ankle Int. 2007;28(2):154-161. doi:10.3113/FAI.2007.0154.
38.
RobinsonDEWinsonIGHarriesWJKellyAJ. Arthroscopic treatment of osteochondral lesions of the talus. J Bone Joint Surg Br. 2003;85(7):989-993. doi:10.1302/0301-620X.85B7.13959.
39.
SalkRSChangTJD’CostaWFSoomekhDJGroganKA. Sodium hyaluronate in the treatment of osteoarthritis of the ankle: a controlled, randomized, double-blind pilot study. J Bone Joint Surg Am. 2006;88(2):295-302. doi:10.2106/JBJS.E.00193.
40.
Savage-ElliottIRossKASmythNAMurawskiCDKennedyJG. Osteochondral lesions of the talus: a current concepts review and evidence-based treatment paradigm. Foot Ankle Spec. 2014;7(5):414-422. doi:10.1177/1938640014543362.
41.
SaxenaAEakinC. Articular talar injuries in athletes: results of microfracture and autogenous bone graft. Am J Sports Med. 2007;35(10):1680-1687. doi:10.1177/0363546507303561.
42.
SchachterAKChenALReddyPDTejwaniNC. Osteochondral lesions of the talus. J Am Acad Orthop Surg. 2005;13(3):152-158.
43.
ShapiroFKoideSGlimcherMJ. Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. J Bone Joint Surg Am. 1993;75(4):532-553.
44.
SimonLS. Viscosupplementation therapy with intra-articular hyaluronic acid. Fact or fantasy?Rheum Dis Clin North Am. 1999;25(2):345-357. doi:10.1016/S0889-857X(05)70072-7.
45.
SolorioLDDhamiCDDangPNViereggeELAlsbergE. Spatiotemporal regulation of chondrogenic differentiation with controlled delivery of transforming growth factor-β1 from gelatin microspheres in mesenchymal stem cell aggregates. Stem Cells Transl Med. 2012;1(8):632-639. doi:10.5966/sctm.2012-0039.
46.
SunSFChouYJHsuCW. Efficacy of intra-articular hyaluronic acid in patients with osteoarthritis of the ankle: a prospective study. Osteoarthr Cartil. 2006;14(9):867-874. doi:10.1016/j.joca.2006.03.003.
47.
SundmanEAColeBJFortierLA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39(10):2135-2140. doi:10.1177/0363546511417792.
48.
Van BueckenKBarrackRLAlexanderAHErtlJP. Arthroscopic treatment of transchondral talar dome fractures. Am J Sports Med. 1989;17(3):350-355. doi:10.1177/036354658901700307.
49.
WitteveenAGGianniniSGuidoG. A prospective multi-centre, open study of the safety and efficacy of hylan G-F 20 (Synvisc) in patients with symptomatic ankle (talo-crural) osteoarthritis. Foot Ankle Surg. 2008;14(3):145-152. doi:10.1016/j.fas.2008.01.001.
50.
WitteveenAGSiereveltINBlankevoortLKerkhoffsGMvan DijkCN. Intra-articular sodium hyaluronate injections in the osteoarthritic ankle joint: effects, safety and dose dependency. Foot Ankle Surg. 2010;16(4):159-163. doi:10.1016/j.fas.2009.10.003.
51.
Woodell-MayJMatuskaAOysterM. Autologous protein solution inhibits MMP-13 production by IL-1beta and TNFalpha-stimulated human articular chondrocytes. J Orthop Res. 2011;29(9):1320-1326. doi:10.1002/jor.21384.
52.
ZengerinkMStruijsPATolJLvan DijkCN. Treatment of osteochondral lesions of the talus: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2010;18(2):238-246. doi:10.1007/s00167-009-0942-6.
